PRELUDE CAPITAL MANAGEMENT, LLC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 2 filers reported holding BRIDGEBIO PHARMA INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$401,193
+22.5%
15,214
-20.1%
0.03%
+23.8%
Q2 2023$327,505
+29.3%
19,041
+24.6%
0.02%
+40.0%
Q1 2023$253,293
+42.0%
15,277
-34.7%
0.02%
+66.7%
Q4 2022$178,31623,4010.01%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 3,835,722$103,449,00044.18%
Kohlberg Kravis Roberts & Co. L.P. 36,900,661$995,211,00012.26%
SC US (TTGP), LTD. 2,544,738$68,632,0004.69%
Cormorant Asset Management, LP 2,780,885$75,000,0004.31%
Perceptive Advisors 6,706,268$180,868,0004.15%
VIKING GLOBAL INVESTORS LP 26,620,991$717,968,0003.22%
Hillhouse Capital Management 2,035,790$54,905,0001.75%
Alpine Group USVI, LLC 20,000$539,0001.70%
HHLR ADVISORS, LTD. 2,352,900$63,458,0001.42%
SCGE MANAGEMENT, L.P. 588,235$15,865,0000.79%
View complete list of BRIDGEBIO PHARMA INC shareholders